• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Excellent humidity sensor based on ultrathin HKUST-1 nanosheets?
  Qiaoe Wang,Meiling Lian,Xiaowen Zhu,Xu Chen RSC Adv., 2021,11, 192-197
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

Professional Introduction to Compound with CAS No. 1806418-95-0 and Product Name: 1-(2,6-Dibromophenyl)propan-2-one

The compound identified by the CAS number 1806418-95-0 and the product name 1-(2,6-Dibromophenyl)propan-2-one represents a significant molecule in the realm of chemical and pharmaceutical research. This compound, featuring a dibromophenyl substituent on a propan-2-one backbone, has garnered attention due to its unique structural properties and potential applications in synthetic chemistry and drug development.

Structurally, 1-(2,6-Dibromophenyl)propan-2-one is characterized by the presence of two bromine atoms at the 2 and 6 positions of a phenyl ring, attached to a propanone group. This specific arrangement imparts distinct electronic and steric properties to the molecule, making it a valuable intermediate in organic synthesis. The dibromophenyl moiety enhances reactivity through electrophilic aromatic substitution reactions, while the propan-2-one segment provides a versatile platform for further functionalization.

In recent years, the pharmaceutical industry has shown increasing interest in molecules containing brominated aromatic rings due to their role as key pharmacophores in various therapeutic agents. The presence of bromine atoms can modulate metabolic stability, binding affinity, and overall bioactivity of drug candidates. For instance, studies have demonstrated that brominated compounds often exhibit enhanced binding interactions with biological targets compared to their non-brominated counterparts.

One of the most compelling aspects of 1-(2,6-Dibromophenyl)propan-2-one is its utility as a building block in medicinal chemistry. Researchers have leveraged this compound to synthesize novel molecules with potential therapeutic applications. Notably, derivatives of this structure have been explored in the development of small-molecule inhibitors targeting various disease pathways. The dibromophenyl group serves as an anchor point for further chemical modifications, allowing chemists to introduce additional functional groups such as hydroxyls, amines, or carboxylic acids.

Recent advancements in computational chemistry have further highlighted the significance of 1-(2,6-Dibromophenyl)propan-2-one. Molecular modeling studies indicate that this compound can adopt multiple conformations depending on its environment, which may influence its interactions with biological targets. These insights have guided experimental efforts to optimize synthetic routes and improve yields of biologically active derivatives. Additionally, computational screening has identified new analogs of this compound with enhanced pharmacokinetic profiles.

The synthesis of 1-(2,6-Dibromophenyl)propan-2-one itself presents an interesting challenge due to the need for precise regioselective bromination of the phenyl ring. Traditional bromination methods often suffer from over-bromination or poor yields when applied to electron-rich aromatic systems. However, recent innovations in catalytic bromination have enabled more efficient and selective preparations of this compound. These advancements have not only improved access to 1-(2,6-Dibromophenyl)propan-2-one but also paved the way for similar derivatives.

In conclusion, the compound with CAS no. 1806418-95-0, known as 1-(2,6-Dibromophenyl)propan-2-one, represents a promising candidate for further research and development in pharmaceutical chemistry. Its unique structural features make it a valuable intermediate for synthesizing novel therapeutic agents targeting various diseases. As research continues to uncover new applications for brominated aromatic compounds, compounds like this are likely to play an increasingly important role in drug discovery and development.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)